This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.
Name: SBRT+TKI
Description: Received SBRT after three months after EGFR-TKI treatmentType: RadiationSBRT+TKI
Name: TKI
Description: Received EGFR-TKI treatmentType: DrugTKI
Description: progression-free survival
Measure: PFS Time: 2 yearsDescription: overall survival
Measure: OS Time: 3 yearAllocation: Randomized
Parallel Assignment
There is one SNP
exon 19 deletion or exon 21 L858R) 10. --- L858R ---